These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36104978)

  • 1. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
    Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
    Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
    Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
    J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
    Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
    Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absent in melanoma 2 (AIM2) positive profile identifies a poor prognosis of lung adenocarcinoma patients.
    Colarusso C; Terlizzi M; Falanga A; Stathopoulos G; De Lucia L; Hansbro PM; Pinto A; Sorrentino R
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110990. PubMed ID: 37857119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
    Yang P; He S; Ye L; Weng H
    Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
    Zhu P; Kang G; Jiao Y; Gui C; Fan H; Li X; Jia Y; Zhang L; Ma X
    Hum Cell; 2022 Jul; 35(4):1207-1218. PubMed ID: 35593989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
    Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
    Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Alanazi M; Weng T; McLeod L; Gearing LJ; Smith JA; Kumar B; Saad MI; Jenkins BJ
    Cancer Sci; 2024 Jun; 115(6):1834-1850. PubMed ID: 38594840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
    Zhou F; Wang X; Liu F; Meng Q; Yu Y
    Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
    Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
    BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
    Qu S; Jiao Z; Lu G; Yao B; Wang T; Rong W; Xu J; Fan T; Sun X; Yang R; Wang J; Yao Y; Xu G; Yan X; Wang T; Liang H; Zen K
    Genome Biol; 2021 Apr; 22(1):104. PubMed ID: 33849634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
    Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.